Kymera Therapeutics Inc. | Mid-cap | Healthcare
$44.10
3.55%
| Kymera Therapeutics Stock Comparison:
Kymera Therapeutics vs VertexKymera Therapeutics vs RegeneronKymera Therapeutics vs BridgeBio PharmaKymera Therapeutics vs MadrigalKymera Therapeutics vs Blueprint MedicinesKymera Therapeutics vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 11.5M
Operating Income -84.6M -736.82%
Net Income -76.6M -667.60%
EPS (Diluted) $-0.95

Balance Sheet Metrics

Total Assets 918.3M
Total Liabilities 132.1M
Shareholders Equity 786.2M
Debt to Equity 0.17

Cash Flow Metrics

Operating Cash Flow -67.7M
Free Cash Flow -79.6M

Revenue & Profitability Trend

Kymera Therapeutics Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i47.1M78.6M46.8M72.8M34.0M
Cost of Goods Sold i-----
Gross Profit i-----
Gross Margin % i0.0%0.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i240.2M189.1M164.2M137.0M62.1M
Selling, General & Administrative i63.5M55.0M43.8M36.3M18.2M
Other Operating Expenses i-----
Total Operating Expenses i303.8M244.1M208.1M173.4M80.3M
Operating Income i-256.7M-165.5M-161.3M-100.5M-46.3M
Operating Margin % i-545.4%-210.6%-344.4%-138.0%-136.1%
Non-Operating Items
Interest Income i38.0M18.8M6.6M488.0K826.0K
Interest Expense i249.0K196.0K176.0K175.0K115.0K
Other Non-Operating Income-4.9M----
Pre-tax Income i-223.9M-147.0M-154.8M-100.2M-45.6M
Income Tax i-----
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-223.9M-147.0M-154.8M-100.2M-45.6M
Net Margin % i-475.6%-187.0%-330.6%-137.6%-134.0%
Key Metrics
EBITDA i-211.3M-143.2M-151.7M-97.6M-43.7M
EPS (Basic) i$-2.98$-2.52$-2.87$-2.09$-3.15
EPS (Diluted) i$-2.98$-2.52$-2.87$-2.09$-3.15
Basic Shares Outstanding i7504399158365499539332294798902317349582
Diluted Shares Outstanding i7504399158365499539332294798902317349582

Income Statement Trend

Kymera Therapeutics Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i120.3M110.0M68.4M48.0M31.0M
Short-term Investments i368.5M264.9M338.8M394.4M265.2M
Accounts Receivable i015.0M00577.0K
Inventory i-----
Other Current Assets20.6M11.7M9.7M8.7M4.7M
Total Current Assets i510.3M405.3M419.4M451.3M302.3M
Non-Current Assets
Property, Plant & Equipment i10.5M42.4M5.5M2.9M1.7M
Goodwill i-----
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets7.7M7.9M9.1M8.1M1.6M
Total Non-Current Assets i467.8M170.4M183.7M154.6M184.8M
Total Assets i978.0M575.8M603.1M605.9M487.2M
Liabilities
Current Liabilities
Accounts Payable i6.0M7.1M4.3M4.0M4.4M
Short-term Debt i13.1M6.3M3.9M3.6M3.3M
Current Portion of Long-term Debt-----
Other Current Liabilities223.0K524.0K303.0K228.0K106.0K
Total Current Liabilities i67.8M85.7M71.3M92.5M110.6M
Non-Current Liabilities
Long-term Debt i74.6M78.3M13.4M14.4M14.7M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities--248.0K66.0K100.0K
Total Non-Current Liabilities i74.6M95.1M41.6M53.7M92.7M
Total Liabilities i142.4M180.8M113.0M146.3M203.3M
Equity
Common Stock i7.0K6.0K6.0K5.0K4.0K
Retained Earnings i-754.6M-530.8M-383.8M-229.0M-128.8M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i835.6M395.0M490.2M459.6M283.9M
Key Metrics
Total Debt i87.8M84.7M17.3M18.0M18.0M
Working Capital i442.5M319.6M348.1M358.7M191.7M

Balance Sheet Composition

Kymera Therapeutics Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-223.9M-147.0M-154.8M-100.2M-45.6M
Depreciation & Amortization i7.4M3.6M3.0M2.4M1.8M
Stock-Based Compensation i55.0M43.1M35.5M25.0M5.2M
Working Capital Changes i-19.2M1.5M-41.2M-70.5M122.9M
Operating Cash Flow i-180.7M-98.8M-157.5M-143.4M84.6M
Investing Activities
Capital Expenditures i-12.8M-34.5M-2.8M-1.6M-9.1M
Acquisitions i-----
Investment Purchases i-901.2M-189.2M-446.0M-456.4M-529.4M
Investment Sales i510.0M363.5M469.3M358.2M115.9M
Investing Cash Flow i-404.1M139.9M20.5M-99.8M-422.6M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i-1.6M-76.0K-1.1M-849.0K-554.0K
Financing Cash Flow i595.0M-76.0K148.7M241.9M289.1M
Free Cash Flow i-207.3M-137.3M-155.9M-130.5M79.0M
Net Change in Cash i10.2M41.0M11.7M-1.3M-48.9M

Cash Flow Trend

Kymera Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -13.94
Forward P/E -13.69
Price to Book 3.09
Price to Sales 68.07
PEG Ratio -0.22

Profitability Ratios

Profit Margin 0.00%
Operating Margin -736.82%
Return on Equity -33.26%
Return on Assets -19.92%

Financial Health

Current Ratio 8.32
Debt to Equity 8.82
Beta 2.18

Per Share Data

EPS (TTM) $-3.49
Book Value per Share $13.77
Revenue per Share $0.56

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
kymr3.0B-13.943.09-33.26%0.00%8.82
Vertex 100.2B27.775.8322.77%31.86%8.89
Regeneron 62.9B14.952.0615.34%31.37%9.04
BridgeBio Pharma 9.6B-17.12-5.2836.76%98.25%-1.04
Madrigal 8.5B-17.6712.12-36.30%-54.68%17.81
Blueprint Medicines 8.4B-120.9924.43-47.71%-27.70%208.50

Financial data is updated regularly. All figures are in the company's reporting currency.